Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Alcaftadine
Cat. No.:
OB0225LY-0154
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Alcaftadine is a new antihistamine that is mainly used for the treatment of eye allergies.
Synonym:
R89674; Lastacaft; 147084-10-4; Alcaftadine; 11-(1-Methylpiperidin-4-ylidene)-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carbaldehyde; 11-(1-Methylpiperidin-4-ylidene)-6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepine-3-carbaldehyde; 11-(1-Methylpiperidin-4-ylidene)-6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine-3-carbaldehyde; 2-(1-Methylpiperidin-4-ylidene)-4,7-diazatricyclo[8.4.0.0(3,7)]tetradeca- 1(14),3,5,10,12-pentaene-6-carbaldehyde
CAS No.:
147084-10-4
Compound CID:
19371515
Formula:
C19H21N3O
Formula Weight:
307.39
Specification
Relative Density:
1.24 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Alcaftadine can be used in ophthalmic allergy studies.
Library Information
Targets:
Histamine receptor
Receptors:
H1 receptor; H2 receptor; H4 receptor
Pathways:
Immunology/Inflammation; GPCR/G protein; Neuronal signaling
Plate Number:
AOCL-2
Plate Location:
h7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
3.85 mg/mL; 12.51 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
61 mg/mL; 198.44 mM
